Inclusion Criteria:

          1. Diagnosis of refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) or
             lymphoblastic lymphoma (T-LBL) according to the NCCN 2019.V2 Guideline. Refractory
             T-ALL is defined as a patient who has failed to achieve complete remission after
             induction therapy. Relapsed T-ALL is defined as the reappearance of blasts (5%) in
             either peripheral blood or bone marrow. Patients whose tumor burden >5% blasts, or who
             have persistent positive minimal residual disease (MRD), or have reappearance of
             extramedullary lesions are also considered eligible.

          2. CD7-positive tumor (≥70% CD7 positive blasts by flow cytometry or immunohistochemistry
             (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory). tumors
             burden >5%,or MRD+， or new extramedullary lesions reappeared.

          3. Life expectancy greater than 12 weeks

          4. KPS or Lansky score≥60

          5. HGB≥70g/L

          6. oxygen saturation of blood>90%

          7. Total bilirubin (TBil)≤3 × upper limit normal, aspartate aminotransferase (AST) and
             alanine aminotransferase (ALT) ≤ 5×upper limit of normal

          8. Informed consent explained to, understood by and signed by patient/guardian.

        Exclusion Criteria:

          1. Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial
             infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT,
             per investigator discretion. Cardiac echocardiography with LVSF (left ventricular
             shortening fraction)<30% or LVEF(left ventricular ejection fraction)<50%; or
             clinically significant pericardial effusion. Cardiac dysfunction NYHA(New York Heart
             Association) III or IV (Confirmation of absence of these conditions on echocardiogram
             within 12 months of treatment)

          2. Has an active GvHD;

          3. Has a history of severe pulmonary function damaging;

          4. With other tumors which is/are in advanced malignant and has/have systemic metastasis;

          5. Severe or persistent infection that cannot be effectively controlled；

          6. Presence of severe autoimmune diseases or immunodeficiency disease;

          7. Patients with active hepatitis B or hepatitis C([HBVDNA+]or [HCVRNA+]);

          8. Patients with HIV infection or syphilis infection;

          9. Has a history of serious allergies to biological products (including antibiotics);

         10. Clinically significant viral infection or uncontrolled viral reactivation of
             EBV(Epstein-Barr virus), CMV(cytomegalovirus), ADV(adenovirus), BK-virus, or HHV(human
             herpesvirus)-6.

         11. Presence of any symtomatic CNS disorder such as an uncontrolled seizure disorder,
             cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune
             disease with CNS involvement;

         12. Received allogeneic hematopoietic stem cell transplantation within 6 months;

         13. Being pregnant and lactating or having pregnancy within 12 months;

         14. Any situations that the researchers believe will increase the risks for the subject or
             affect the results of the study.